Vectura Group plc Results of General Meeting (5145P)
10 Ottobre 2019 - 2:17PM
UK Regulatory
TIDMVEC
RNS Number : 5145P
Vectura Group plc
10 October 2019
Results of General Meeting
Results of the General Meeting held on 10 October 2019 at the
offices of Clifford Chance LLP, 4 Coleman Street, London EC2R
5JJ.
Chippenham, UK - 10 October 2019: Vectura Group plc (LSE: VEC)
("Vectura" or "the Company") announces that all resolutions
proposed to shareholders at its General Meeting (GM) held today
were duly passed on a poll, the results of which are set out
below:
Resolution No. of votes % No. of % No. of % No. of
for & discretionary votes total votes votes
against cast withheld
To declare
a Special
Dividend
of 6 pence
per ordinary
share in
the capital
of the Company 506,185,673 99.93 370,136 0.07 506,555,809 75.99 6,605
--------------------- -------- ------------ ------- -------------- -------- ----------
To approve
the share
consolidation
as set out
in the Circular 505,701,857 99.83 836,694 0.17 506,538,551 75.99 23,863
--------------------- -------- ------------ ------- -------------- -------- ----------
To authorise
market purchases
of the Company's
own shares* 501,388,488 99.05 4,822,433 0.95 506,210,921 75.94 351,493
--------------------- -------- ------------ ------- -------------- -------- ----------
* Passed as a special resolution.
Votes 'withheld' have not been included in the calculation of
whether a resolution is carried.
A copy of the resolutions as well as the above results will
shortly be available on the Company's website at
https://www.vectura.com/investors/stock-exchange-announcements.
A copy of the resolutions will be submitted to the National
Storage Mechanism and in due course will be available to view at
http://www.morningstar.co.uk/uk/NSM using Vectura Group PLC's code
'VEC'.
As at the close of business on 10 October 2019, the issued share
capital was 666,581,058 ordinary shares of GBP0.00025 each,
carrying one vote each. At 10 October 2019 the Company did not hold
any shares in treasury. Therefore, the total number of voting
rights in the Company as at 10 October 2019 was 666,581,058.
- Ends-
For more information, please contact:
Vectura Group plc
Elizabeth Knowles - VP Investor Relations +44 (0)7767 160 565
David Ginivan - VP Corporate Communications +44 (0)7471 352 720
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / David Daley
About Vectura
Vectura is a provider of innovative inhaled drug delivery
solutions that enable partners to bring their medicines to
patients. With differentiated proprietary technology and
pharmaceutical development expertise, Vectura is one of the few
companies globally with the device, formulation and development
capabilities to deliver a broad range of complex inhaled
therapies.
Vectura has ten key inhaled and eleven non-inhaled products
marketed by partners with global royalty streams, and a diverse
partnered portfolio of drugs in clinical development. Our partners
include Hikma, Novartis, Sandoz (a division of Novartis AG),
Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin
KingYork.
For further information, please visit Vectura's website at
www.vectura.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMFFMFESFUSEFS
(END) Dow Jones Newswires
October 10, 2019 08:17 ET (12:17 GMT)
Grafico Azioni Vectura (LSE:VEC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Vectura (LSE:VEC)
Storico
Da Apr 2023 a Apr 2024
